Matthew Dankner

Employment

Employment history is unavailable.

Education

• McGill University MD/PhD
  2015 - Present

Projects & Funding

Projects & funding information is unavailable.

Publications (24)

• Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers
  JCO Precision Oncology 2025 3 citations DOI: 10.1200/PO.24.00199
  +Save
• Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis
  Current Oncology 2025 2 citations DOI: 10.3390/curroncol32110624
  +Save
• The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
  Current Oncology 2024 9 citations DOI: 10.3390/curroncol32010001
  +Save
• Antibody–Drug Conjugates for the Treatment of Non-Small Cell Lung Cancer with Central Nervous System Metastases
  Current Oncology 2024 6 citations DOI: 10.3390/curroncol31100471
  +Save
• Invasive growth of brain metastases is linked to CHI3L1 release from pSTAT3-positive astrocytes
  Neuro-Oncology 2024 31 citations DOI: 10.1093/neuonc/noae013
  +Save
• The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers
  Cancers 2024 12 citations DOI: 10.3390/cancers16020445
  +Save
• The clinical, genomic, and transcriptomic landscape of BRAF mutant cancers
  2023 1 citation DOI: 10.1101/2023.09.15.557847
  +Save
• Gender Disparities in Academic Outcomes Among Graduates of a Canadian MD-PhD Program.
  Clinical and investigative medicine. Medecine clinique et experimentale 2023 4 citations DOI: 10.25011/cim.v46i1.39965
  +Save
• Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors
  JCO Precision Oncology 2022 49 citations DOI: 10.1200/PO.22.00107
  +Save
• Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumors
  2022 1 citation DOI: 10.1101/2022.02.17.22271120
  +Save